Helix BioPharma Corp. has appointed Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO) to lead its clinical development strategy as the company prepares for a more execution-focused phase. Dr. Loeffler brings over three decades of oncology drug development experience, having held senior roles at Roche, Advanced Accelerator Applications, and other biotech firms. He notably led the pivotal Phase III program for Lutathera®, a radiopharmaceutical approved for neuroendocrine tumors.
The appointment comes at a critical juncture for Helix, which is advancing L-DOS47, an antibody-enzyme conjugate, into a planned Phase Ib/II trial in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC). The company is also preparing LEUMUNA™, an oral immune checkpoint modulator, for clinical development in leukemia relapse following stem cell transplantation. Dr. Loeffler's expertise in immunotherapies and combination strategies is expected to be instrumental in navigating these complex trials.
CEO Thomas Mehrling highlighted his previous collaboration with Dr. Loeffler, praising his ability to translate innovative science into well-executed clinical programs. Dr. Loeffler expressed enthusiasm about advancing L-DOS47 with checkpoint inhibition and bringing LEUMUNA to the clinic, aiming to provide new treatment options for difficult-to-treat cancers.
Helix BioPharma focuses on oncology therapies for underserved patient populations. Its pipeline includes L-DOS47, LEUMUNA, and GEMCEDA™, a gemcitabine prodrug for advanced solid tumors. The company's shares are listed on the TSX, OTC Pink, and Frankfurt Stock Exchange. More information is available at Helix BioPharma.
Dr. Loeffler's appointment signals a strategic push to execute clinical milestones efficiently, which could enhance the company's position in the competitive oncology landscape. His track record of advancing therapies through regulatory approval brings credibility and experience that may be pivotal for Helix's future success.
